This article was originally published in The Gray Sheet
Executive SummarySign agreement under which CooperSurgical, a subsidiary of The Cooper Companies, will fund development and clinical trials of InnerDyne's thermal ablation technology for gynecological applications. Sunnyvale, California-based InnerDyne's system, still under development, uses heated saline for the control of excessive uterine bleeding. Upon completion of early clinicals and an assessment of feasibility, CooperSurgical will have the option to purchase exclusive worldwide commercialization rights to the technology for an undisclosed initial sum, plus royalties on sales
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.